You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameBenazepril
Accession NumberDB00542  (APRD00063)
TypeSmall Molecule
GroupsApproved, Investigational
Description

Benazepril, brand name Lotensin, is a medication used to treat high blood pressure (hypertension), congestive heart failure, and chronic renal failure. Upon cleavage of its ester group by the liver, benazepril is converted into its active form benazeprilat, a non-sulfhydryl angiotensin-converting enzyme (ACE) inhibitor.

Structure
Thumb
Synonyms
1H-1-Benzazepine-1-acetic acid, 3-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-2,3,4,5-tetrahydro-2-oxo-, (S-(r*,r*))-
Benazepril
Benazeprilum
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Benazepriltablet10 mgoralAa Pharma Inc2007-05-15Not applicableCanada
Benazepriltablet5 mgoralAa Pharma Inc2007-05-15Not applicableCanada
Benazepriltablet20 mgoralAa Pharma Inc2006-03-24Not applicableCanada
Lotensintablet40 mg/1oralNovartis Pharmaceuticals Corporation1991-06-252016-01-01Us
Lotensintablet20 mg/1oralNovartis Pharmaceuticals Corporation1991-06-252016-02-01Us
Lotensintablet20 mg/1oralPd Rx Pharmaceuticals, Inc.1991-06-25Not applicableUs
Lotensintablet5 mg/1oralPhysicians Total Care, Inc.1996-12-30Not applicableUs
Lotensintablet40 mg/1oralPhysicians Total Care, Inc.1999-02-24Not applicableUs
Lotensintablet20 mg/1oralPhysicians Total Care, Inc.1994-03-23Not applicableUs
Lotensintablet10 mg/1oralPhysicians Total Care, Inc.2003-11-04Not applicableUs
Lotensintablet40 mg/1oralValidus Pharmaceuticals LLC1991-06-25Not applicableUs
Lotensintablet20 mg/1oralValidus Pharmaceuticals LLC1991-06-25Not applicableUs
Lotensin 10mgtablet10 mgoralNovartis Pharmaceuticals Canada Inc1993-12-312012-09-11Canada
Lotensin 20mgtablet20 mgoralNovartis Pharmaceuticals Canada Inc1993-12-31Not applicableCanada
Lotensin 5mgtablet5 mgoralNovartis Pharmaceuticals Canada Inc1993-12-31Not applicableCanada
PMS-benazepriltablet10 mgoralPharmascience IncNot applicableNot applicableCanada
PMS-benazepriltablet20 mgoralPharmascience IncNot applicableNot applicableCanada
PMS-benazepriltablet5 mgoralPharmascience IncNot applicableNot applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Benazepriltablet20 mg/1oralSTAT Rx USA LLC2010-02-02Not applicableUs
Benazepriltablet, coated40 mg/1oralInternational Laboratories, Inc.2013-09-19Not applicableUs
Benazepril Hydrochloridetablet, coated20 mg/1oralPreferred Pharmaceuticals, Inc.2015-04-14Not applicableUs
Benazepril Hydrochloridetablet, film coated10 mg/1oralAurobindo Pharma Limited2008-05-22Not applicableUs
Benazepril Hydrochloridetablet, film coated40 mg/1oralBlenheim Pharmacal, Inc.2013-11-13Not applicableUs
Benazepril Hydrochloridetablet, film coated20 mg/1oralbryant ranch prepack2010-09-06Not applicableUs
Benazepril Hydrochloridetablet, film coated10 mg/1oralMylan Pharmaceuticals Inc.2004-02-11Not applicableUs
Benazepril Hydrochloridetablet, coated20 mg/1oralNorthwind Pharmaceuticals, LLC2016-03-04Not applicableUs
Benazepril Hydrochloridetablet, coated5 mg/1oralTeva Pharmaceuticals USA Inc2004-02-11Not applicableUs
Benazepril Hydrochloridetablet, coated10 mg/1oralPreferred Pharmaceuticals, Inc.2015-03-25Not applicableUs
Benazepril Hydrochloridetablet5 mg/1oralAv Kare, Inc.2009-07-29Not applicableUs
Benazepril Hydrochloridetablet, film coated5 mg/1oralRebel Distributors Corp.2004-02-11Not applicableUs
Benazepril Hydrochloridetablet10 mg/1oralBlenheim Pharmacal, Inc.2013-11-14Not applicableUs
Benazepril Hydrochloridetablet, film coated10 mg/1oralMylan Institutional Inc.2004-05-21Not applicableUs
Benazepril Hydrochloridetablet20 mg/1oralREMEDYREPACK INC.2011-06-16Not applicableUs
Benazepril Hydrochloridetablet, film coated20 mg/1oralApotex Corp2006-04-21Not applicableUs
Benazepril Hydrochloridetablet10 mg/1oralAv Kare, Inc.2010-07-29Not applicableUs
Benazepril Hydrochloridetablet, film coated20 mg/1oralCardinal Health2011-08-16Not applicableUs
Benazepril Hydrochloridetablet, film coated40 mg/1oralRanbaxy Pharmaceuticals Inc.2004-02-11Not applicableUs
Benazepril Hydrochloridetablet, film coated20 mg/1oralMylan Institutional Inc.2004-05-21Not applicableUs
Benazepril Hydrochloridetablet, coated5 mg/1oralProficient Rx LP2014-01-01Not applicableUs
Benazepril Hydrochloridetablet, film coated40 mg/1oralApotex Corp2006-04-21Not applicableUs
Benazepril Hydrochloridetablet, film coated40 mg/1oralPreferred Pharmaceuticals, Inc2010-09-06Not applicableUs
Benazepril Hydrochloridetablet40 mg/1oralAmneal Pharmaceuticals of New York, LLC2010-02-02Not applicableUs
Benazepril Hydrochloridetablet20 mg/1oralBlenheim Pharmacal, Inc.2013-11-08Not applicableUs
Benazepril Hydrochloridetablet, film coated5 mg/1oralMylan Pharmaceuticals Inc.2004-02-11Not applicableUs
Benazepril Hydrochloridetablet, coated20 mg/1oralInternational Laboratories, Inc.2014-02-01Not applicableUs
Benazepril Hydrochloridetablet, film coated10 mg/1oralLake Erie Medical DBA Quality Care Products LLC2010-09-06Not applicableUs
Benazepril Hydrochloridetablet, film coated20 mg/1oralRebel Distributors Corp.2004-02-11Not applicableUs
Benazepril Hydrochloridetablet, film coated40 mg/1oralUnit Dose Services2010-09-06Not applicableUs
Benazepril Hydrochloridetablet, coated20 mg/1oralMedsource Pharmaceuticals2014-01-01Not applicableUs
Benazepril Hydrochloridetablet, film coated10 mg/1oralApotex Corp2006-04-16Not applicableUs
Benazepril Hydrochloridetablet, coated5 mg/1oralPhysicians Total Care, Inc.2005-08-19Not applicableUs
Benazepril Hydrochloridetablet, film coated20 mg/1oralRanbaxy Pharmaceuticals Inc.2004-02-11Not applicableUs
Benazepril Hydrochloridetablet, coated10 mg/1oralProficient Rx LP2014-01-01Not applicableUs
Benazepril Hydrochloridetablet, film coated20 mg/1oralPreferred Pharmaceuticals, Inc2010-09-06Not applicableUs
Benazepril Hydrochloridetablet20 mg/1oralAmneal Pharmaceuticals of New York, LLC2010-02-02Not applicableUs
Benazepril Hydrochloridetablet40 mg/1oralMajor Pharmaceuticals2010-02-02Not applicableUs
Benazepril Hydrochloridetablet, film coated10 mg/1oralRebel Distributors Corp.2004-02-11Not applicableUs
Benazepril Hydrochloridetablet, film coated20 mg/1oralEon Labs, Inc.2004-02-11Not applicableUs
Benazepril Hydrochloridetablet, coated40 mg/1oralInternational Laboratories, Inc.2014-02-01Not applicableUs
Benazepril Hydrochloridetablet, film coated20 mg/1oralLake Erie Medical DBA Quality Care Products LLC2010-09-06Not applicableUs
Benazepril Hydrochloridetablet10 mg/1oralStat Rx USA2009-10-27Not applicableUs
Benazepril Hydrochloridetablet, film coated10 mg/1oralUnit Dose Services2010-09-06Not applicableUs
Benazepril Hydrochloridetablet, film coated20 mg/1oralPd Rx Pharmaceuticals, Inc.2010-09-06Not applicableUs
Benazepril Hydrochloridetablet, film coated5 mg/1oralApotex Corp2006-04-16Not applicableUs
Benazepril Hydrochloridetablet, coated40 mg/1oralPhysicians Total Care, Inc.2005-01-05Not applicableUs
Benazepril Hydrochloridetablet, film coated10 mg/1oralRanbaxy Pharmaceuticals Inc.2004-02-11Not applicableUs
Benazepril Hydrochloridetablet10 mg/1oralDIRECT RX2014-01-01Not applicableUs
Benazepril Hydrochloridetablet, film coated10 mg/1oralPreferred Pharmaceuticals, Inc2010-09-06Not applicableUs
Benazepril Hydrochloridetablet10 mg/1oralAmneal Pharmaceuticals of New York, LLC2010-02-02Not applicableUs
Benazepril Hydrochloridetablet20 mg/1oralMajor Pharmaceuticals2010-02-02Not applicableUs
Benazepril Hydrochloridetablet, coated40 mg/1oralSolco healthcare U.S., LLC2014-01-01Not applicableUs
Benazepril Hydrochloridetablet, film coated5 mg/1oralEon Labs, Inc.2004-02-11Not applicableUs
Benazepril Hydrochloridetablet, coated40 mg/1oralLake Erie Medical DBA Quality Care Products LLC2014-01-01Not applicableUs
Benazepril Hydrochloridetablet, film coated40 mg/1oralLake Erie Medical DBA Quality Care Products LLC2010-09-06Not applicableUs
Benazepril Hydrochloridetablet, film coated20 mg/1oralUnit Dose Services2010-09-06Not applicableUs
Benazepril Hydrochloridetablet, coated10 mg/1oralPd Rx Pharmaceuticals, Inc.2004-02-11Not applicableUs
Benazepril Hydrochloridetablet, film coated20 mg/1oralGolden State Medical Supply, Inc.2015-07-15Not applicableUs
Benazepril Hydrochloridetablet, coated20 mg/1oralPhysicians Total Care, Inc.2004-08-25Not applicableUs
Benazepril Hydrochloridetablet, film coated5 mg/1oralRanbaxy Pharmaceuticals Inc.2004-02-11Not applicableUs
Benazepril Hydrochloridetablet, coated20 mg/1oralREMEDYREPACK INC.2015-06-15Not applicableUs
Benazepril Hydrochloridetablet10 mg/1oralMajor Pharmaceuticals2010-02-02Not applicableUs
Benazepril Hydrochloridetablet, coated20 mg/1oralSolco healthcare U.S., LLC2014-01-01Not applicableUs
Benazepril Hydrochloridetablet, film coated10 mg/1oralEon Labs, Inc.2004-02-11Not applicableUs
Benazepril Hydrochloridetablet40 mg/1oralPreferred Pharmaceuticals Inc.2016-01-11Not applicableUs
Benazepril Hydrochloridetablet40 mg/1oralAidarex Pharmaceuticals LLC2010-02-02Not applicableUs
Benazepril Hydrochloridetablet, film coated40 mg/1oralTrigen Laboratories, Inc.2012-11-15Not applicableUs
Benazepril Hydrochloridetablet40 mg/1oralAv Pak2014-04-15Not applicableUs
Benazepril Hydrochloridetablet, coated40 mg/1oralPd Rx Pharmaceuticals, Inc.2004-02-11Not applicableUs
Benazepril Hydrochloridetablet, film coated10 mg/1oralGolden State Medical Supply, Inc.2015-07-15Not applicableUs
Benazepril Hydrochloridetablet, coated10 mg/1oralPhysicians Total Care, Inc.2004-05-17Not applicableUs
Benazepril Hydrochloridetablet, film coated40 mg/1oralRanbaxy Pharmaceuticals Inc.2010-09-06Not applicableUs
Benazepril Hydrochloridetablet, coated10 mg/1oralREMEDYREPACK INC.2015-06-15Not applicableUs
Benazepril Hydrochloridetablet, film coated5 mg/1oralPreferred Pharmaceuticals, Inc2010-09-06Not applicableUs
Benazepril Hydrochloridetablet5 mg/1oralAmneal Pharmaceuticals of New York, LLC2010-02-02Not applicableUs
Benazepril Hydrochloridetablet20 mg/1oralAidarex Pharmaceuticals LLC2010-02-02Not applicableUs
Benazepril Hydrochloridetablet, film coated20 mg/1oralTrigen Laboratories, Inc.2012-11-15Not applicableUs
Benazepril Hydrochloridetablet20 mg/1oralAv Pak2014-04-15Not applicableUs
Benazepril Hydrochloridetablet, coated20 mg/1oralPd Rx Pharmaceuticals, Inc.2011-09-29Not applicableUs
Benazepril Hydrochloridetablet, film coated5 mg/1oralGolden State Medical Supply, Inc.2015-07-15Not applicableUs
Benazepril Hydrochloridetablet, film coated20 mg/1oralInternational Laboratories, Inc.2009-03-01Not applicableUs
Benazepril Hydrochloridetablet, film coated20 mg/1oralRanbaxy Pharmaceuticals Inc.2010-09-06Not applicableUs
Benazepril Hydrochloridetablet, film coated40 mg/1oralSt Marys Medical Park Pharmacy2014-01-15Not applicableUs
Benazepril Hydrochloridetablet40 mg/1oralAmerican Health Packaging2014-05-27Not applicableUs
Benazepril Hydrochloridetablet, coated40 mg/1oralbryant ranch prepack2004-02-11Not applicableUs
Benazepril Hydrochloridetablet5 mg/1oralMajor Pharmaceuticals2010-02-02Not applicableUs
Benazepril Hydrochloridetablet, coated10 mg/1oralSolco healthcare U.S., LLC2014-01-01Not applicableUs
Benazepril Hydrochloridetablet, coated40 mg/1oralTeva Pharmaceuticals USA Inc2004-02-11Not applicableUs
Benazepril Hydrochloridetablet, film coated10 mg/1oralPreferred Pharmaceuticals, Inc2012-01-12Not applicableUs
Benazepril Hydrochloridetablet10 mg/1oralAv Pak2014-04-15Not applicableUs
Benazepril Hydrochloridetablet40 mg/1oralAv Kare, Inc.2009-07-29Not applicableUs
Benazepril Hydrochloridetablet, coated5 mg/1oralPd Rx Pharmaceuticals, Inc.2011-06-24Not applicableUs
Benazepril Hydrochloridetablet, film coated10 mg/1oralRanbaxy Pharmaceuticals Inc.2010-09-06Not applicableUs
Benazepril Hydrochloridetablet20 mg/1oralSt Marys Medical Park Pharmacy2014-01-15Not applicableUs
Benazepril Hydrochloridetablet, film coated40 mg/1oralAurobindo Pharma Limited2008-05-22Not applicableUs
Benazepril Hydrochloridetablet, film coated5 mg/1oralbryant ranch prepack2010-09-06Not applicableUs
Benazepril Hydrochloridetablet, film coated40 mg/1oralMylan Pharmaceuticals Inc.2004-02-11Not applicableUs
Benazepril Hydrochloridetablet, coated5 mg/1oralSolco healthcare U.S., LLC2014-01-01Not applicableUs
Benazepril Hydrochloridetablet, coated20 mg/1oralTeva Pharmaceuticals USA Inc2004-02-11Not applicableUs
Benazepril Hydrochloridetablet, film coated20 mg/1oralPreferred Pharmaceuticals, Inc2012-01-12Not applicableUs
Benazepril Hydrochloridetablet10 mg/1oralAidarex Pharmaceuticals LLC2010-02-02Not applicableUs
Benazepril Hydrochloridetablet, film coated10 mg/1oralTrigen Laboratories, Inc.2012-11-15Not applicableUs
Benazepril Hydrochloridetablet, film coated5 mg/1oralRanbaxy Pharmaceuticals Inc.2010-09-06Not applicableUs
Benazepril Hydrochloridetablet10 mg/1oralSt. Mary's Medical Park Pharmacy2015-06-16Not applicableUs
Benazepril Hydrochloridetablet, film coated20 mg/1oralAurobindo Pharma Limited2008-05-22Not applicableUs
Benazepril Hydrochloridetablet, coated10 mg/1oralbryant ranch prepack2009-06-29Not applicableUs
Benazepril Hydrochloridetablet, film coated20 mg/1oralMylan Pharmaceuticals Inc.2004-02-11Not applicableUs
Benazepril Hydrochloridetablet, film coated5 mg/1oralPreferred Pharmaceuticals Inc.2016-03-15Not applicableUs
Benazepril Hydrochloridetablet, coated10 mg/1oralTeva Pharmaceuticals USA Inc2004-02-11Not applicableUs
Benazepril Hydrochloridetablet, film coated40 mg/1oralPreferred Pharmaceuticals, Inc2012-01-12Not applicableUs
Benazepril Hydrochloridetablet, film coated40 mg/1oralRebel Distributors Corp.2004-02-11Not applicableUs
Benazepril Hydrochloridetablet, film coated5 mg/1oralTrigen Laboratories, Inc.2012-11-15Not applicableUs
Benazepril Hydrochloridetablet5 mg/1oralAv Pak2014-04-14Not applicableUs
Benazepril Hydrochloridetablet20 mg/1oralAv Kare, Inc.2009-07-29Not applicableUs
Benazepril Hydrochloridetablet, film coated10 mg/1oralCardinal Health2011-08-16Not applicableUs
Benazepril Hydrochloridetablet, film coated20 mg/1oralNorthwind Pharmaceuticals2014-05-30Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
BriemPierre Fabre (France)
CibacenNovartis (Belgium, Philippines, Switzerland, Turkey), Meda (Denmark, Germany, Greece, Ireland, Italy, Netherlands, Spain)
CibaceneMeda (France)
Brand mixtures
NameLabellerIngredients
AmlobenzRebel Distributors Corp
Amlodipine and Benazepril HydrochlorideTeva Pharmaceuticals USA Inc
Amlodipine Besylate and Benazepril HClAmerican Health Packaging
Amlodipine Besylate and Benazepril HydrochlorideActavis Pharma, Inc.
Benazepril Hydrochloride and HydrochlorothiazideEon Labs, Inc.
Lotensin HctValidus Pharmaceuticals LLC
LotrelNovartis Pharmaceuticals Corporation
Salts
Name/CASStructureProperties
Benazepril Hydrochloride
Thumb
  • InChI Key: VPSRQEHTHIMDQM-FKLPMGAJSA-N
  • Monoisotopic Mass: 460.176499755
  • Average Mass: 460.95
DBSALT000554
Categories
UNIIUDM7Q7QWP8
CAS number86541-75-5
WeightAverage: 424.4895
Monoisotopic: 424.199822016
Chemical FormulaC24H28N2O5
InChI KeyInChIKey=XPCFTKFZXHTYIP-PMACEKPBSA-N
InChI
InChI=1S/C24H28N2O5/c1-2-31-24(30)20(14-12-17-8-4-3-5-9-17)25-19-15-13-18-10-6-7-11-21(18)26(23(19)29)16-22(27)28/h3-11,19-20,25H,2,12-16H2,1H3,(H,27,28)/t19-,20-/m0/s1
IUPAC Name
2-[(3S)-3-{[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}-2-oxo-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl]acetic acid
SMILES
CCOC(=O)[[email protected]](CCC1=CC=CC=C1)N[[email protected]]1CCC2=CC=CC=C2N(CC(O)=O)C1=O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as alpha amino acid esters. These are ester derivatives of alpha amino acids.
KingdomOrganic compounds
Super ClassOrganic acids and derivatives
ClassCarboxylic acids and derivatives
Sub ClassAmino acids, peptides, and analogues
Direct ParentAlpha amino acid esters
Alternative Parents
Substituents
  • Alpha-amino acid ester
  • Benzazepine
  • Phenylpropylamine
  • Aralkylamine
  • Fatty acid ester
  • Azepine
  • Fatty acyl
  • Benzenoid
  • Dicarboxylic acid or derivatives
  • Monocyclic benzene moiety
  • Tertiary carboxylic acid amide
  • Tertiary amine
  • Lactam
  • Carboxylic acid ester
  • Carboxamide group
  • Azacycle
  • Organoheterocyclic compound
  • Secondary amine
  • Secondary aliphatic amine
  • Carboxylic acid
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationFor the treatment of hypertension. It may be used alone or in combination with thiazide diuretics.
PharmacodynamicsBenazepril, an angiotensin-converting enzyme (ACE) inhibitor, is a prodrug which, when hydrolyzed by estarases to its active Benazeprilat, is used to treat hypertension and heart failure, to reduce proteinuria and renal disease in patients with nephropathies, and to prevent stroke, myocardial infarction, and cardiac death in high-risk patients. Benazepril and Benazeprilat inhibit angiotensin-converting enzyme (ACE) in human subjects and animals. ACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the vasoconstrictor substance, angiotensin II. Angiotensin II also stimulates aldosterone secretion by the adrenal cortex.
Mechanism of actionBenazeprilat, the active metabolite of Benazepril, competes with angiotensin I for binding at the angiotensin-converting enzyme, blocking the conversion of angiotensin I to angiotensin II. Inhibition of ACE results in decreased plasma angiotensin II. As angiotensin II is a vasoconstrictor and a negative-feedback mediator for renin activity, lower concentrations result in a decrease in blood pressure and stimulation of baroreceptor reflex mechanisms, which leads to decreased vasopressor activity and to decreased aldosterone secretion. Benazeprilat may also act on kininase II, an enzyme identical to ACE that degrades the vasodilator bradykinin.
Related Articles
AbsorptionPeak in plasma within 0.5-1.0 hours. The extent of absorption is at least 37% as determined by urinary recovery and is not significantly influenced by the presence of food in the GI tract.
Volume of distributionNot Available
Protein bindingbenazepril, 97%; benazeprilat, 95%
Metabolism

Cleavage of the ester group (primarily in the liver) converts benazepril to its active metabolite, benazeprilat. Benazepril and benazeprilat may be conjugated to glucuronic acid prior to urinary excretion.

SubstrateEnzymesProduct
Benazepril
Not Available
benazeprilatDetails
Route of eliminationBenazepril and benazeprilat are cleared predominantly by renal excretion in healthy subjects with normal renal function. Nonrenal (i.e., biliary) excretion accounts for approximately 11%-12% of benazeprilat excretion in healthy subjects.
Half life10-11 hours
Clearance
  • 0.35 L/hr/kg [pediatric hypertensive patients receiving multiple daily doses of Benazepril hydrochloride 0.1 – 0.5 mg/kg]
  • 0.13 L/hr/kg [healthy adults receiving a single dose of 10 mg]
ToxicityMost likely symptom of overdosage is severe hypotension. Most common adverse effects include headache, dizziness, fatigue, somnolence, postural dizziness, nausea, and cough.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Benazepril Metabolism PathwayDrug metabolismSMP00591
Benazepril Action PathwayDrug actionSMP00145
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.5732
Blood Brain Barrier-0.7082
Caco-2 permeable-0.7279
P-glycoprotein substrateSubstrate0.8466
P-glycoprotein inhibitor IInhibitor0.7426
P-glycoprotein inhibitor IINon-inhibitor0.7565
Renal organic cation transporterNon-inhibitor0.8239
CYP450 2C9 substrateNon-substrate0.7518
CYP450 2D6 substrateNon-substrate0.8563
CYP450 3A4 substrateSubstrate0.5632
CYP450 1A2 substrateNon-inhibitor0.8232
CYP450 2C9 inhibitorNon-inhibitor0.6875
CYP450 2D6 inhibitorNon-inhibitor0.8266
CYP450 2C19 inhibitorInhibitor0.5461
CYP450 3A4 inhibitorInhibitor0.5425
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6038
Ames testNon AMES toxic0.8377
CarcinogenicityNon-carcinogens0.9435
BiodegradationNot ready biodegradable0.9713
Rat acute toxicity2.2082 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9787
hERG inhibition (predictor II)Inhibitor0.6696
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Apotex inc etobicoke site
  • Aurobindo pharma ltd
  • Biokey inc
  • Genpharm inc
  • Huahai us inc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Mylan pharmaceuticals inc
  • Ranbaxy laboratories ltd
  • Sandoz inc
  • Teva pharmaceuticals usa inc
  • Watson laboratories inc florida
  • Zydus pharmaceuticals usa inc
  • Novartis pharmaceuticals corp
Packagers
Dosage forms
FormRouteStrength
Tabletoral10 mg
Tabletoral10 mg/1
Tabletoral40 mg/1
Tabletoral5 mg/1
Tablet, coatedoral10 mg/1
Tablet, coatedoral20 mg/1
Tablet, coatedoral40 mg/1
Tablet, coatedoral5 mg/1
Tablet, film coatedoral10 mg/1
Tablet, film coatedoral20 mg/1
Tablet, film coatedoral40 mg/1
Tablet, film coatedoral5 mg/1
Tablet, coatedoral
Tablet, film coatedoral
Tabletoral20 mg/1
Tabletoral20 mg
Tabletoral5 mg
Tabletoral
Capsuleoral
Prices
Unit descriptionCostUnit
Lotensin 20 mg tablet2.08USD tablet
Lotensin 10 mg tablet2.0USD tablet
Lotensin 40 mg tablet2.0USD tablet
Lotensin 5 mg tablet2.0USD tablet
Lotensin HCT 20-12.5 mg tablet1.97USD tablet
Lotensin HCT 10-12.5 mg tablet1.95USD tablet
Lotensin HCT 20-25 mg tablet1.94USD tablet
Lotensin hct 10-12.5 tablet1.9USD tablet
Lotensin hct 20-12.5 tablet1.9USD tablet
Lotensin hct 20-25 tablet1.9USD tablet
Lotensin hct 5-6.25 tablet1.9USD tablet
Lotensin HCT 5-6.25 mg tablet1.31USD tablet
Lotensin 20 mg Tablet1.14USD tablet
Benazepril hcl 10 mg tablet1.07USD tablet
Benazepril hcl 20 mg tablet1.07USD tablet
Benazepril hcl 40 mg tablet1.07USD tablet
Benazepril hcl 5 mg tablet1.07USD tablet
Lotensin 10 mg Tablet0.99USD tablet
Lotensin 5 mg Tablet0.84USD tablet
Apo-Benazepril 20 mg Tablet0.79USD tablet
Apo-Benazepril 10 mg Tablet0.69USD tablet
Apo-Benazepril 5 mg Tablet0.58USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6162802 No1997-12-192017-12-19Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point148.5 °CPhysProp
water solubility2.229 mg/LNot Available
logP3.3Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0105 mg/mLALOGPS
logP1.14ALOGPS
logP1.54ChemAxon
logS-4.6ALOGPS
pKa (Strongest Acidic)3.53ChemAxon
pKa (Strongest Basic)5.36ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area95.94 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity115.23 m3·mol-1ChemAxon
Polarizability44.98 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis Reference

Wei-Hong Tseng, “ASYMMETRIC SYNTHESIS OF A KEY INTERMEDIATE FOR MAKING BENAZEPRIL AND ANALOGUES THEREOF.” U.S. Patent US20020183515, issued December 05, 2002.

US20020183515
General References
  1. Chan KK, Buch A, Glazer RD, John VA, Barr WH: Site-differential gastrointestinal absorption of benazepril hydrochloride in healthy volunteers. Pharm Res. 1994 Mar;11(3):432-7. [PubMed:8008712 ]
  2. De Feo P, Torlone E, Perriello G, Fanelli C, Epifano L, Di Vincenzo A, Modarelli F, Motolese M, Brunetti P, Bolli GB: Short-term metabolic effects of the ACE-inhibitor benazepril in type 2 diabetes mellitus associated with arterial hypertension. Diabete Metab. 1992 Jul-Aug;18(4):283-8. [PubMed:1459316 ]
  3. Gengo FM, Brady E: The pharmacokinetics of benazepril relative to other ACE inhibitors. Clin Cardiol. 1991 Aug;14(8 Suppl 4):IV44-50; discussion IV51-5. [PubMed:1893642 ]
  4. Hou FF, Zhang X, Zhang GH, Xie D, Chen PY, Zhang WR, Jiang JP, Liang M, Wang GB, Liu ZR, Geng RW: Efficacy and safety of benazepril for advanced chronic renal insufficiency. N Engl J Med. 2006 Jan 12;354(2):131-40. [PubMed:16407508 ]
  5. Ishimitsu T, Akashiba A, Kameda T, Takahashi T, Ohta S, Yoshii M, Minami J, Ono H, Numabe A, Matsuoka H: Benazepril slows progression of renal dysfunction in patients with non-diabetic renal disease. Nephrology (Carlton). 2007 Jun;12(3):294-8. [PubMed:17498126 ]
  6. MacNab M, Mallows S: Safety profile of benazepril in essential hypertension. Clin Cardiol. 1991 Aug;14(8 Suppl 4):IV33-7; discussion IV51-5. [PubMed:1893640 ]
  7. Szekacs B, Vajo Z, Dachman W: Effect of ACE inhibition by benazepril, enalapril and captopril on chronic and post exercise proteinuria. Acta Physiol Hung. 1996;84(4):361-7. [PubMed:9328608 ]
External Links
ATC CodesC09AA07C09BA07
AHFS Codes
  • 24:32.04
PDB Entries
FDA labelDownload (237 KB)
MSDSDownload (57.5 KB)
Interactions
Drug Interactions
Drug
Acetylsalicylic acidAcetylsalicylic acid may decrease the antihypertensive activities of Benazepril.
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Benazepril.
AlfuzosinAlfuzosin may increase the hypotensive activities of Benazepril.
AliskirenAliskiren may increase the hyperkalemic activities of Benazepril.
AllopurinolThe risk of a hypersensitivity reaction to Allopurinol is increased when it is combined with Benazepril.
AmifostineBenazepril may increase the hypotensive activities of Amifostine.
AprotininAprotinin may decrease the antihypertensive activities of Benazepril.
ArdeparinArdeparin may increase the hyperkalemic activities of Benazepril.
AzathioprineBenazepril may increase the myelosuppressive activities of Azathioprine.
BrimonidineBrimonidine may increase the antihypertensive activities of Benazepril.
ButabarbitalButabarbital may increase the hypotensive activities of Benazepril.
ButethalButethal may increase the hypotensive activities of Benazepril.
CanagliflozinCanagliflozin may increase the hyperkalemic activities of Benazepril.
CiprofloxacinBenazepril may increase the arrhythmogenic activities of Ciprofloxacin.
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Benazepril.
DiazoxideDiazoxide may increase the hypotensive activities of Benazepril.
DrospirenoneBenazepril may increase the hyperkalemic activities of Drospirenone.
DuloxetineBenazepril may increase the orthostatic hypotensive activities of Duloxetine.
EplerenoneEplerenone may increase the hyperkalemic activities of Benazepril.
EverolimusThe risk or severity of adverse effects can be increased when Everolimus is combined with Benazepril.
HeparinHeparin may increase the hyperkalemic activities of Benazepril.
HeptabarbitalHeptabarbital may increase the hypotensive activities of Benazepril.
HexobarbitalHexobarbital may increase the hypotensive activities of Benazepril.
HydrochlorothiazideHydrochlorothiazide may increase the hypotensive activities of Benazepril.
IcatibantIcatibant may decrease the antihypertensive activities of Benazepril.
InfliximabThe risk or severity of adverse effects can be increased when Benazepril is combined with Infliximab.
IronThe risk or severity of adverse effects can be increased when Benazepril is combined with Iron.
Iron DextranThe risk or severity of adverse effects can be increased when Benazepril is combined with Iron Dextran.
LanthanumThe serum concentration of Benazepril can be decreased when it is combined with Lanthanum.
LevodopaBenazepril may increase the orthostatic hypotensive activities of Levodopa.
LithiumThe serum concentration of Lithium can be increased when it is combined with Benazepril.
MethohexitalMethohexital may increase the hypotensive activities of Benazepril.
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Benazepril.
MolsidomineMolsidomine may increase the hypotensive activities of Benazepril.
MoxonidineMoxonidine may increase the hypotensive activities of Benazepril.
NicorandilNicorandil may increase the hypotensive activities of Benazepril.
ObinutuzumabBenazepril may increase the hypotensive activities of Obinutuzumab.
PentobarbitalPentobarbital may increase the hypotensive activities of Benazepril.
PentoxifyllinePentoxifylline may increase the hypotensive activities of Benazepril.
PhenelzinePhenelzine may increase the orthostatic hypotensive activities of Benazepril.
PregabalinThe risk or severity of adverse effects can be increased when Benazepril is combined with Pregabalin.
PrimidonePrimidone may increase the hypotensive activities of Benazepril.
QuinineQuinine may increase the hypotensive activities of Benazepril.
RisperidoneBenazepril may increase the hypotensive activities of Risperidone.
RituximabBenazepril may increase the hypotensive activities of Rituximab.
SacubitrilThe risk or severity of adverse effects can be increased when Benazepril is combined with Sacubitril.
SecobarbitalSecobarbital may increase the hypotensive activities of Benazepril.
SirolimusThe risk or severity of adverse effects can be increased when Sirolimus is combined with Benazepril.
SitagliptinThe risk or severity of adverse effects can be increased when Sitagliptin is combined with Benazepril.
Sodium aurothiomalateThe risk or severity of adverse effects can be increased when Benazepril is combined with Sodium aurothiomalate.
TadalafilTadalafil may increase the antihypertensive activities of Benazepril.
TemsirolimusThe risk or severity of adverse effects can be increased when Temsirolimus is combined with Benazepril.
TizanidineTizanidine may increase the hypotensive activities of Benazepril.
TolvaptanTolvaptan may increase the hyperkalemic activities of Benazepril.
TorasemideTorasemide may increase the hypotensive activities of Benazepril.
TranylcypromineTranylcypromine may increase the orthostatic hypotensive activities of Benazepril.
TreprostinilTreprostinil may increase the hypotensive activities of Benazepril.
TriamtereneTriamterene may increase the hyperkalemic activities of Benazepril.
TrichlormethiazideTrichlormethiazide may increase the hypotensive activities of Benazepril.
TrimethoprimTrimethoprim may increase the hyperkalemic activities of Benazepril.
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Benazepril.
VardenafilVardenafil may increase the antihypertensive activities of Benazepril.
YohimbineYohimbine may decrease the antihypertensive activities of Benazepril.
Food Interactions
  • Benazepril may decrease the excretion of potassium. Salt um may increase the risk of hyperkalemia. substitutes containing potassi
  • Food slows absorption without decreasing the quantity absorbed.
  • Herbs that may attenuate the antihypertensive effect of benazepril include: bayberry, blue cohash, cayenne, ephedra, ginger, ginseng (American), kola and licorice.
  • High salt intake may attenuate the antihypertensive effect of benazepril.
  • Take without regard to meals.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Zinc ion binding
Specific Function:
Converts angiotensin I to angiotensin II by release of the terminal His-Leu, this results in an increase of the vasoconstrictor activity of angiotensin. Also able to inactivate bradykinin, a potent vasodilator. Has also a glycosidase activity which releases GPI-anchored proteins from the membrane by cleaving the mannose linkage in the GPI moiety.
Gene Name:
ACE
Uniprot ID:
P12821
Molecular Weight:
149713.675 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Song JC, White CM: Clinical pharmacokinetics and selective pharmacodynamics of new angiotensin converting enzyme inhibitors: an update. Clin Pharmacokinet. 2002;41(3):207-24. [PubMed:11929321 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Protein complex binding
Specific Function:
Catalyzes the conversion of 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate, a co-substrate for homocysteine remethylation to methionine.
Gene Name:
MTHFR
Uniprot ID:
P42898
Molecular Weight:
74595.895 Da
References
  1. Jiang S, Yu Y, Venners SA, Zhang Y, Xing H, Wang X, Xu X: Effects of MTHFR and MS gene polymorphisms on baseline blood pressure and Benazepril effectiveness in Chinese hypertensive patients. J Hum Hypertens. 2011 Mar;25(3):172-7. doi: 10.1038/jhh.2010.50. Epub 2010 May 6. [PubMed:20445573 ]
  2. Jiang S, Hsu YH, Niu T, Xu X, Xing H, Chen C, Wang X, Zhang Y, Peng S, Xu X: A common haplotype on methylenetetrahydrofolate reductase gene modifies the effect of angiotensin-converting enzyme inhibitor on blood pressure in essential hypertension patients--a family-based association study. Clin Exp Hypertens. 2005 Aug;27(6):509-21. [PubMed:16081343 ]
  3. Jiang S, Hsu YH, Xu X, Xing H, Chen C, Niu T, Zhang Y, Peng S, Xu X: The C677T polymorphism of the methylenetetrahydrofolate reductase gene is associated with the level of decrease on diastolic blood pressure in essential hypertension patients treated by angiotensin-converting enzyme inhibitor. Thromb Res. 2004;113(6):361-9. [PubMed:15226090 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Proton-dependent oligopeptide secondary active transmembrane transporter activity
Specific Function:
Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides. May constitute a major route for the absorption of protein digestion end-products.
Gene Name:
SLC15A1
Uniprot ID:
P46059
Molecular Weight:
78805.265 Da
References
  1. Knutter I, Wollesky C, Kottra G, Hahn MG, Fischer W, Zebisch K, Neubert RH, Daniel H, Brandsch M: Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008 Nov;327(2):432-41. doi: 10.1124/jpet.108.143339. Epub 2008 Aug 19. [PubMed:18713951 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Peptide:proton symporter activity
Specific Function:
Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides.
Gene Name:
SLC15A2
Uniprot ID:
Q16348
Molecular Weight:
81782.77 Da
References
  1. Knutter I, Wollesky C, Kottra G, Hahn MG, Fischer W, Zebisch K, Neubert RH, Daniel H, Brandsch M: Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008 Nov;327(2):432-41. doi: 10.1124/jpet.108.143339. Epub 2008 Aug 19. [PubMed:18713951 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on July 01, 2016 01:50